British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, ...

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its ...

A new tuberculosis (TB) vaccine candidate, M72/AS01E, has entered Phase III clinical trials, with Kenyans among the 20,000 ...

LONDON (Reuters) -British drugmaker GSK said on Wednesday it is in talks with the Trump administration about ways to lower U.S. drug costs, becoming the latest pharmaceutical company to acknowledge ...

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

With the stock's last traded price at Rs 3,081, GlaxoSmithKline Pharmaceuticals has experienced a notable decline, positioning it among the top losers on the Nifty Midcap 150 index.

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

"Uveal Melanoma Market Insight, Epidemiology and Market Forecast - 2034"The uveal melanoma treatment market is experiencing ...

GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure. | GSK’s cobolimab has ...

Jiangsu Hengrui Pharmaceuticals' shares surged 10% to a 4-year high after licensing HRS-9821 and 11 programs to ...